Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with a specific type of brain lymphoma called CD20+ B-cell primary central nervous system lymphoma (PCNSL), confirmed through tissue, fluid, or cell testing and documented in a pathology report.
• People who have already completed a first course of chemotherapy that included a high-dose methotrexate (at least 3 grams per square metre of body surface area), with or without brain radiation.
• People who finished that first treatment within the past 75 days before joining the trial, and whose lymphoma responded to that treatment (either partial or complete response).
• People who had a brain MRI scan within the last 30 days showing that the lymphoma responded to treatment.
• People whose lymphoma was found in their spinal fluid or eyes during diagnosis or first treatment, and who have since had repeat testing confirming the lymphoma is no longer detectable in those areas (confirm with trial site for exact MRI and imaging requirements).
• People who have not used corticosteroid medications for at least two weeks at the time their response to treatment is assessed.
• People with a reasonable level of physical functioning, as measured by standard medical scales (Karnofsky score of 60 or above, or ECOG score of 0, 1, or 2).
• People whose liver function, kidney function, and blood counts fall within acceptable ranges, based on blood tests taken within 7 days before joining the trial (confirm specific values with trial site).
• People who are either surgically unable to have children, or who agree to use effective contraception during treatment and for at least 18 months after the last dose (for women) or 180 days (for men).
• People willing and able to follow all study requirements and who have signed a consent form.

Who may not be able to join:

• People who have had a severe allergic or anaphylactic reaction to monoclonal antibody therapies in the past.
• People who have lymphoma outside the brain or central nervous system.
• People with a known allergy to any of the study medications.
• People with a history of another cancer that could interfere with the study or its results — though people previously treated for certain skin cancers or cervical cancer in situ may still be considered eligible (confirm with trial site).
• People with another cancer that was treated without the goal of a cure, unless that cancer has been in remission without any treatment for at least 2 years before joining the trial.
• People with a known active infection (bacterial, viral, fungal, or other), or who needed intravenous antibiotics or hospitalisation for an infection within the 4 weeks before joining the trial.
• People who have had major surgery within the 4 weeks before joining the trial.
• People known to be living with HIV.
• People who test positive for hepatitis B surface antigen or certain hepatitis B antibodies — though some cases may be considered individually if additional testing is negative (confirm with trial site).
• People who test positive for hepatitis C, unless further testing confirms the virus is not active — some cases may be considered individually (confirm with trial site).
• People who are pregnant or breastfeeding.
• People who received a live vaccine less than 4 weeks before joining the trial.

Important: Always verify eligibility with the trial site directly before applying.